What's Going On With Aldeyra Therapeutics Stock On Thursday?

Benzinga_recent_news03-19

Since Tuesday, the company’s stock has slumped by around 67%. The company received an FDA Complete Response Letter (CRL) for its New Drug Application for reproxalap, indicating a lack of substantial ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620225604?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/19/Doctor-Working-On-Virtual-Touch-Screen-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-19 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620225604","market":"us","top_or_hot":-1,"title":"What's Going On With Aldeyra Therapeutics Stock On Thursday?","media":"Benzinga_recent_news","content":"<div>\n<p>Since Tuesday, the company’s stock has slumped by around 67%.\nThe company received an FDA Complete Response Letter (CRL) for its New Drug Application for reproxalap, indicating a lack of substantial ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Aldeyra Therapeutics Stock On Thursday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Aldeyra Therapeutics Stock On Thursday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Since Tuesday, the company’s stock has slumped by around 67%.\nThe company received an FDA Complete Response Letter (CRL) for its New Drug Application for reproxalap, indicating a lack of substantial ...</p>\n\n<a href=\"https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday","article_id":"2620225604","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/19/Doctor-Working-On-Virtual-Touch-Screen-P.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/03/51352510/whats-going-on-with-aldeyra-therapeutics-stock-on-thursday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620225604","pubTimestamp":1773925260,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Aldeyra stock plunges after FDA rejects its dry eye drug reproxalap, raising concerns over efficacy and future growth prospects.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","SMA":"Smartstop Self Storage REIT Inc","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4139":"生物科技","ALDX":"Aldeyra Therapeutics Inc","BK4121":"生命科学工具和服务","BK4217":"自存仓储房地产信托","LABU":"三倍做多标普生物-Direxion","BK4530":"医药外包概念","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","CRL":"查尔斯河","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4588":"碎股"},"translate_title":"周四Aldeyra Therapeutics股票走势如何？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMA":1,"ALDX":1.5,"LABU":0.66,"CRL":1},"content_text":"Since Tuesday, the company’s stock has slumped by around 67%.\nThe company received an FDA Complete Response Letter (CRL) for its New Drug Application for reproxalap, indicating a lack of substantial evidence from controlled studies.\nThe FDA’s letter raised concerns over the efficacy of reproxalap, stating that further trials are not recommended, but suggested exploring specific populations where the drug may be effective.\nIn a statement, Aldeyra’s CEO emphasized the urgency of collaborating with the FDA to enable market access for reproxalap, which is viewed as a potential breakthrough treatment.\nAs of December 31, 2025, the company reported having $70 million in cash, which is expected to support operations into 2028.\nIn April 2025, the FDA issued a Complete Response Letter for Aldeyra's resubmission of the reproxalap application.\nIn November 2023, the FDA issued a Complete Response Letter to the initial NDA stating that at least one additional symptom trial was required.\nAldeyra Therapeutics is currently trading 69.9% below its 20-day simple moving average (SMA) and 71.2% below its 200-day SMA, indicating a bearish trend.\nShares have decreased 78.42% over the past 12 months and are positioned closer to their 52-week lows than highs.\nThe RSI is at 20.25, which is considered oversold, suggesting potential for a rebound if buying interest returns.\nMeanwhile, the MACD shows a value of -0.6382, with the signal line at -0.2362, indicating bearish momentum as the MACD remains below the signal line.\nThe combination of an oversold RSI and bearish MACD suggests mixed momentum, indicating that while the stock is oversold, there is still downward pressure.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating. Recent analyst moves include:\nALDX Stock Price Activity: Aldeyra Therapeutics shares were down 2.09% at $1.39 during premarket trading on Thursday, according to Benzinga Pro data.\nImage via Shutterstock\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620225604","isCrawlerRequest":true}